Neural intervention systems provider Alcyone Lifesciences has signed an exclusive clinical collaboration agreement with biotechnology firm DNAtrix for brain cancer.
Under the deal, DNAtrix will use Alcyone’s MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix’s lead product to treat aggressive form of brain cancer called glioblastoma (GBM).
The AMC targeted delivery system has been developed by using the firm’s microelectromechanical system (MEMS) technology platform.
It can be used with any existing commercial imaging and stereotactic system in conjunction with the work-flow friendly clinical use guideline.
Alcyone Lifesciences founder and CEO PJ Anand said: "Our micron sized microelectromechanical system (MEMS) based multi-channeled tip and other proprietary features are specifically designed to address the key challenges of optimized and targeted bio-distribution, in addition to avoiding the blood brain barrier for novel biologics such as those pioneered by DNAtrix."
Under intra-procedural MRI guidance, neurosurgeons can select a target, navigate the AMC precisely to the target and observe in real-time the precision delivery of the therapeutic agent.
The AMC features a patented distal end design that helps to avoid reflux or back flow along the cannula shaft, in addition to the MEMS tip which has dual micro-channels.
DNX-2401 is a conditionally-replicative oncolytic adenovirus, which has been engineered to specifically target a large number of tumor cell types.
Image: DNAtrix will use Alcyone’s MEMS Cannula targeted delivery platform for the intratumoral delivery of DNX-2401. Photo: courtesy of PRNewswire/ Alcyone Lifesciences, Inc.